Skip to main content
JUBILANT PHARMOVA LIMITED logo

JUBILANT PHARMOVA LIMITED — Investor Relations & Filings

Ticker · JUBLPHARMA ISIN · INE700A01033 LEI · 335800C6LDKWF4HQH833 BSE.NS Manufacturing
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2023-03-24 Regulatory Filings
Country IN India
Listing BSE.NS JUBLPHARMA

About JUBILANT PHARMOVA LIMITED

https://www.jubilantpharmova.com/

Jubilant Pharmova Limited is an integrated global pharmaceutical company operating through three primary segments: Pharmaceuticals, Contract Research and Development Services (CRDS), and Proprietary Novel Drugs. The Pharmaceuticals segment specializes in radiopharmaceuticals for nuclear medicine, allergy immunotherapy, and the development and manufacturing of generic formulations. It also provides Contract Development and Manufacturing Organization (CDMO) services for sterile injectables and non-sterile products. The CRDS division offers comprehensive drug discovery and development solutions to biopharmaceutical companies worldwide. Furthermore, the Proprietary Novel Drugs segment focuses on creating innovative therapies for oncology and autoimmune diseases. The company leverages its advanced manufacturing infrastructure and research capabilities to serve global markets with a focus on complex chemistry and specialized healthcare solutions.

Recent filings

Filing Released Lang Actions
Trading Window
Regulatory Filings Classification · 95% confidence The document is a short notice informing about the closure of the trading window for designated persons due to upcoming financial results announcement. It is related to insider trading compliance and does not contain any financial data, report, or detailed information about financial results. It is an announcement related to regulatory compliance and trading restrictions, not a financial report or management information. The document length is only 1215 characters, indicating it is a brief announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-03-24 English
Updates
Capital/Financing Update Classification · 95% confidence The document is a press release announcing an additional loan facility from the Government of Canada for the expansion of Jubilant Pharmova Limited's Montreal manufacturing facility. It is addressed to stock exchanges and references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content focuses on a financing update related to a loan facility and expansion project, not on financial results, management changes, or regulatory filings. The document length is 7804 characters, which is sufficient for a detailed announcement but does not contain financial statements or detailed financial analysis. Therefore, this document fits best under the category of Capital/Financing Update (CAP).
2023-03-16 English
Copy of Newspaper Publication
Proxy Solicitation & Information Statement Classification · 95% confidence The document contains a letter dated March 14, 2023, addressed to stock exchanges regarding submission of newspaper advertisements for a Postal Ballot. It includes copies of advertisements published in newspapers related to the dispatch of notices for the Postal Ballot. The content is primarily about the announcement and procedural communication related to shareholder voting via Postal Ballot, not the actual voting results or detailed meeting materials. There is no detailed financial data, management discussion, or report content. The document is a formal communication to stock exchanges for information and record purposes, indicating it is an announcement related to shareholder voting process rather than the voting results or meeting materials themselves. Therefore, the document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is about the dispatch of notices for Postal Ballot and advertisements thereof, it aligns more with Proxy Solicitation & Information Statement (PSI) which covers materials sent to shareholders to provide information and request votes for meetings. The document is not a report publication announcement or regulatory filing as it contains substantive communication about the voting process. Confidence is high due to clear references to Postal Ballot notices and advertisements for shareholder voting.
2023-03-14 English
Shareholders meeting
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice of a Postal Ballot sent to shareholders of Jubilant Pharmova Limited. It includes information about the voting process, the appointment of an independent director, regulatory references to the Companies Act, SEBI Listing Regulations, and instructions for electronic voting. It is not a financial report, earnings release, or management discussion. It is a formal communication to shareholders seeking approval via postal ballot, which is a form of shareholder meeting notice and voting solicitation. This fits the category of Proxy Solicitation & Information Statement (PSI), as it provides information and requests votes for a shareholder meeting resolution.
2023-03-13 English
Updates
Regulatory Filings Classification · 95% confidence The document is a press release dated March 8, 2023, from Jubilant Pharmova Limited announcing the USFDA inspection classification of their API manufacturing facility as 'Voluntary Action Indicated (VAI)'. It is a communication pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which typically requires disclosure of material events. The document does not contain financial statements or detailed financial analysis, nor does it present a full report. It is an announcement of a regulatory inspection outcome, not a full audit report or annual/interim report. The document length is 4459 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-03-08 English
Change in Director(s)
Board/Management Information Classification · 100% confidence The document is an official announcement regarding the appointment of Mr. Shirish G. Belapure as an Additional Director (Non-Executive, Independent) of Jubilant Pharmova Limited. It references compliance with SEBI Listing Regulations and provides details about the director's profile and terms of appointment. There is no financial data, earnings information, or report attached. The content clearly fits the category of announcements related to changes in the company's board of directors. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 4096 characters, which is sufficient for a detailed announcement but not a full report.
2023-03-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.